Editing Inflammation (section)

==== Emerging treatments ====

Recent developments in the treatment of atherosclerosis have focused on addressing inflammation directly. New anti-inflammatory drugs, such as monoclonal antibodies targeting IL-1β, have been studied in large clinical trials, showing promising results in reducing cardiovascular events.<ref>{{cite journal | vauthors = Szekely Y, Arbel Y | title = A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today? | journal = Cardiology and Therapy | volume = 7 | issue = 1 | pages = 25–44 | date = June 2018 | pmid = 29417406 | pmc = 5986669 | doi = 10.1007/s40119-018-0104-3 }}</ref> These drugs offer a potential new avenue for treatment, particularly for patients who do not respond adequately to statins. However, concerns about long-term safety and cost remain significant barriers to widespread adoption.